Dr. Silbermann highlights trial design priorities for multiple myeloma, from supportive care to diverse enrollment

Dr. Rebecca Silbermann, an associate professor at Oregon Health & Science University, outlined key considerations for designing multiple myeloma clinical trials. She stressed the importance of aligning supportive care resources with trial protocols, especially when community sites lack the infrastructure of academic centers.

The discussion emphasized careful selection of trial endpoints that reflect real‑world outcomes and the need to incorporate strategies that improve enrollment of underrepresented patient groups. Silbermann noted that thoughtful resource allocation can help translate trial data into everyday practice.

She also addressed specific safety management, citing cytokine release syndrome handling for patients receiving the bispecific antibody talquetamab‑tgvs (Talvey). The insights were presented at the CoMMit Consortium session during the 2025 ASH Annual Meeting.

Overall, the commentary serves as a guide for investigators aiming to design robust, inclusive multiple myeloma studies that are feasible across varied clinical settings.